Product Information for the Patient
Juluca 50 mg/25 mg Film-Coated Tablets
dolutegravir/rilpivirina
Read this entire product information carefully before starting to take this medicine, as it contains important information for you.
-This medicine has been prescribed only for you, and you should not give it to others even if they have the same symptoms as you, as it may harm them.
Juluca is a medication that contains two active ingredients used to treat infection by the human immunodeficiency virus (HIV-1): dolutegravir and rilpivirine. Dolutegravir belongs to a group of medicationscalled antiretrovirals known as integrase inhibitors (INI)
and rilpivirine belongs to a group of antiretroviral medications called non-nucleoside reverse transcriptase inhibitors (ITINN).Juluca is used to treat HIV-1 infectionin adults aged 18 years and older who are taking other antiretrovirals and whose HIV-1 infection is under control sinceat least6 months. Juluca may replace current antiretroviral medications.
Juluca maintains the level of HIV-1 virus in the body at a low level. This helps to maintain the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that are important for helping your body to fight off infections.
Do not take Juluca:
Do not take Juluca if you are taking any of the following medicinesas they may affectthe way Juluca works:
If you are taking any of the above, consult your doctor about alternatives.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medicine.
Allergic reactions
Juluca contains dolutegravir. Dolutegravir may cause a severe allergic reaction known as hypersensitivity reaction. You need to know the important signs and symptoms to look out for while taking Juluca.
Liver problems including hepatitis B and/or C
Inform your doctor if you have or have hadliver problems, including hepatitis B and/or C. Your doctor will assess the severity of your liver disease before deciding if you can take this medicine.
Be aware of the important symptoms
Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:
You need to know the important signs and symptoms to look out for while taking Juluca.
Children and adolescents
This medicine should not be used in children or adolescents under 18 years, as it has not been studied in these patients.
Other medicines and Juluca
Inform your doctor if you are taking, have taken recently or may need to take any other medicine.
Julucashould not be takenwith some other medicines (see“Do not take Juluca” in section 2):
Some medicines may affect the way Juluca works, orincrease the risk of side effects. Juluca may also affect the way some other medicines work.
Inform your doctorif you are taking any of the following medicines:
Pregnancy
If you are pregnant,think you may be pregnantor intend to become pregnant:
Juluca is not recommended for use.Consult your doctorfor advice.
Inform your doctor immediately if you become pregnant or intend to become pregnant. Your doctor will review your treatment. Do not stop taking Juluca without consulting your doctor, as this may harm you and your baby.
Breastfeeding
Juluca is not recommendedfor women with HIV as the infection can be transmitted to the baby through breast milk.
A small amount of the component, dolutegravir, in Juluca may pass into breast milk. It is unknown if the other component, rilpivirina, may pass into breast milk.
If you are breastfeeding, or think you may be breastfeeding,you should consult your doctor as soon as possible.
Driving and using machines
Julucamay make you feel dizzy, tired or drowsy and have other side effectsthat make you less alert.
Juluca contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult him before taking this medicine.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Rifabutina
Rifabutina, a medication to treat some bacterial infections, may decrease the amount of Juluca in the body and make it less effective.
If you take rifabutina, your doctor may need to give you an additional dose of rilpivirina. Take the rilpivirina tablet at the same time as you take Juluca.
Antacids
Antacids, used to treat indigestion and stomach heartburn, may interrupt the absorption of Juluca in the body and make it less effective.
Do not take an antacid during the 6 hours before taking Juluca, or at least 4 hours after taking it.
Calcium supplements, iron supplements, or multivitamin preparations
Calcium supplements, iron supplements, or multivitamin preparations may interrupt the absorption of Juluca in the body and make it less effective.
Calcium or iron supplements, or multivitamin preparations should be taken at the same time as Juluca. Juluca should be taken with a meal.
If you cannot take these supplements at the same time as Juluca, do not take calcium, iron, or multivitamin supplements during the 6 hours before taking Juluca, or at least 4 hours after taking it.
Antagonists of H2 receptors (e.g., cimetidina, famotidina, nizatidina, ranitidina)
Medications that are antagonists of H2 receptors may interrupt the absorption of Julucain the bodyand make it less effective. Do not take these medications during the 12 hours before taking Juluca, or at least 4 hours after taking it.
If you take more Juluca than you should
If you exceed the number of Juluca tablets,contact your doctor or pharmacist immediately. If possible, show them the Juluca packaging.
If you forget to take Juluca
If you realize you have forgotten a dose before 12 hours have passed since your usual Juluca-taking time, take it as soon as possible. The Juluca tablet should be taken with a meal, and then take the next one at your usual time. If more than 12 hours have passed since your usual Juluca-taking time, skip the missed dose and then take the next one at your usual time.
If you vomit before 4 hours have passed since taking Juluca, take another tablet with a meal. If you vomit more than 4 hours after taking Juluca, you do not need to take another tablet until the next dose.
Do not interrupt treatment with Juluca
Takethis medicationuntil your doctor tells you to. Do not stop taking it unless your doctor tells you to.
If you have any other doubts about using this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.Therefore, it is very important that you inform your doctor of any change in your health.
Allergic reactions
Juluca contains dolutegravir. Dolutegravir can cause a severe allergic reaction known ashypersensitivity reaction. This is a rare reaction (can affect up to 1 in 100 people) that takes dolutegravir. If you have any of the following symptoms:
Very common side effects
These can affectmore than 1 in 10people:
Very common side effects that can appear in your blood tests are:
Common side effects
These can affectup to 1 in 10people:
Common side effects that can appear in your blood tests are:
Uncommon side effects
These can affectup to 1 in 100 people:
Rare side effects
These can affectup to 1 in 10,000 people:
Side effects of unknown frequency
The frequency cannot be estimated from the available data:
Other possible side effects
People taking combination therapy for HIV may have other side effects.
Symptoms of infection and inflammation
People with advanced HIV infection (AIDS) have a weakened immune system and are more likely to develop serious infections (opportunistic infections). They may develop symptoms of infection, caused by old and hidden infections that become active when the body fights them. The symptoms usually includefever, as well as some of the following:
In rare cases, as the immune systembecomes stronger, it may also attack healthy tissues (autoimmune disorders). The symptoms of autoimmune disorders may appear many monthsafterstarting to take HIV medicines. The symptoms may include:
If you have any symptoms of infectionor if you notice any of the above symptoms:
Joint pain, stiffness, and bone problems
Some people taking combination therapy for HIV developosteonecrosis. In this condition, parts of the bone tissue die due to reduced blood supply to the bones. People may be more prone to this condition:
The signs of osteonecrosis include:
If you notice any of these symptoms:
Effects on weight, lipids, and blood glucose
During HIV treatment, there may be an increase in weight and levels of lipids and blood glucose. This is partly related to the recovery of health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will evaluate these changes.
Reporting side effects
If you experience any type of side effect, consult your doctororpharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly throughthenational reporting system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and the bottle after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture. Keep the bottle perfectly closed. Do not remove the desiccant.
This medication does not require any special storage temperature.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Juluca
Appearance of the product and contents of the pack
Juluca film-coated tablets are pink, oval, biconvex, and engraved with “SV J3T” on one side.
Film-coated tablets are presented in child-resistant containers.
Each container contains 30 film-coated tablets and a desiccant to reduce humidity. Once the container has been opened, keep the desiccant in it, do not remove it.
Multiple pack sizes are also available with 90 film-coated tablets (3 packs of 30 film-coated tablets).
Only some pack sizes may be marketed.
Marketing authorization holder
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Netherlands
Responsible for manufacturing
Glaxo Wellcome, S.A.
Avda. Extremadura, 3
09400 Aranda de Duero
Burgos
Spain
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel:+ 32 (0)10 85 65 00 | Lietuva ViiV Healthcare BV Tel: +370 80000334 |
Luxembourg/Luxemburg ViiV Healthcaresrl/bv Belgique/Belgien Tél/Tel:+ 32 (0)10 85 65 00 | |
Ceská republika GlaxoSmithKline, s.r.o. Tel: + 420 222 001 111 | Magyarország ViiV Healthcare BV Tel.:+36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf.: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: +356 80065004 |
Deutschland ViiV Healthcare GmbH Tel.:+ 49 (0)89203 0038-10 | Nederland ViiV Healthcare BV Tel: + 31 (0)332081199 |
Eesti ViiV Healthcare BV Tel:+372 8002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλ?δα GlaxoSmithKlineΜονοπρ?σωπηA.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 |
España Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 | Polska GSKServicesSp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél.: + 33 (0)1 39 17 69 69 | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA Tel: + 351 21 094 08 01 |
Hrvatska ViiV Healthcare BV Tel:+385 800787089 | România ViiV Healthcare BV Tel:+40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel:+386 80688869 |
Ísland Vistor hf. Sími:+354 535 7000 | Slovenská republika ViiV Healthcare BV Tel:+421 800500589 |
Italia ViiV Healthcare S.r.l Tel: + 39 (0)457741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κ?προς ViiV Healthcare BV Τηλ:+357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 |
Latvija ViiV Healthcare BV Tel:+371 80205045 | United Kingdom(Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 |
Last update of this leaflet:
Other sources of information
Further information on this medicine is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.